Evgen Pharma Share Discussion Threads

[nobbygnome] 07/2/2021 16:10

>> mr greedy

You said it 'means' 'the results (are) positive'. That suggests they know the results already when the safety committee can't unblind the data for a month. So please tell us how he can know the results are 'positive' when no-one know who got drug and who got placebo? It's that sort of statement which leads to false expectations.

[mesquida] 07/2/2021 16:06

Yes, Nobbygnome, i too was impressed ( not a lot ) by the reaction of the regulators to the recent attempt by a number of private investors to bloody the noses of professional shorters.
But as Bumpa says....
"If you're hoping for a level playing field, forget it".

[mr greedy1] 07/2/2021 15:58

6947 - small nob. Try reading English. I made no reference that we can expect immediate results. Only that the Prof will not be backing a loser and must have knowledge/understanding of even the 86 reported. As he is compiling the information for submission, I certainly hope he has the understanding!

"I guess if Prof Chambers has come on board it means the 100 reached and the results positive".

I will be surprised if the coming week is going to be uninteresting.

But I could be wrong - no mention of the appointments, flat lining share price etc.

[nobbygnome] 07/2/2021 15:46

>> mesquida

Post 6956. Very well said. The reality is that the PIs have been thoroughly worked over and our potential profit severely limited. Meanwhile as you say a load of city insiders get to buy cheap shares and profit straight away from a ridiculously low share price which has been managed down for over a year.

It's an absolute disgrace and the management of EVG are complicit in the mugging of share holders. The FCA ought to be investigating these sorts of events but nobody cares because it's only PIs who get hurt. It's only when IIs are adversely affected as in GameStop do the regulators then get interested. As I say it's absolutely disgraceful!

Cue a hissy fit...

[moneymunch] 07/2/2021 15:39

Hi mesquida, as I said the other day..."needs must" and I'm more than happy with the £11m cash plus c£2m in the bank and Evgen's undoubted Transformational near, mid and long term prospects, and sure we've got double amount of shares, but somewhat immaterial from such a low market cap, given the potential upside ahead...as positive news is hopefully delivered...£1 a share now equates to market cap of c£257m and so not out of the question on any commercialisation of SFX-01 for one of their multiple targets....and so a ten bagger from now on in..Gl ;-)

[mesquida] 07/2/2021 15:26

Bumpa, "trust me, i know" suggests that you might be (or might once have been ) in the broking/investment industry. Am i right ?

[mesquida] 07/2/2021 15:19

A thought provoking reply Bumpa, thanks for that even if it is all slightly depressing, but i will take good heed of your final paragraph, and also the penultimate paragraph, sound advice which i need to adopt otherwise i could do my head in !

[bumpa33] 07/2/2021 14:54

Mesquida - I have no love for Finncap but there really are NO better options out there when you are at the bottom of the stock mkt pile - trust me, I know. WH Ireland, Turner Pope, Optiva, Peterhouse, Beaumont Cornish, Novum, Allenby, Brandon Hill, share price Angel etc etc - many I rate WAY lower than Finncap in the ‘running roughshod over company/shareholder’ stakes.

Maybe you think we could attract a Cenkos, a Shore Cap, Peel Hunt or some other lower mid tier broker? Dream on, we’re not of sufficient standing - yet.

Junior pharma with no revenue rarely - if ever - have the ability to call the shots on price, that’s just how it is.

You either sit and bemoan the fact the smart money wants in now, or you follow the smart money.

If you’re hoping for a level playing field, forget it. Think pragmatism rather than idealism.

[mesquida] 07/2/2021 14:48

Just re-visited a previous post of mine, numbered 6626 on 22 January.....
"Personally i rather hope that the new man changes the house broker before he considers any plcing ".

[mesquida] 07/2/2021 14:40

Well you are right about one thing, moneymunch, the smart money IS flooding in, but the problem for us long term shareholders is that due to the shehanigans of FinnCap the money is flooding in when the stock price is at an artificially depressed level. The way in which this placing played out does not seem to bother you at all, you continue to bombard the board wih bullish references to Sulforaphane without ever mentioning the horrible dilution that we have just suffered. I suspect that you perhaps don't understand that ultimately the level of a share price will always be a function of the number of shares that are in issue. What perhaps you should focus on is that now we will be sharing the potential rewards of what could admittedly be a ground-breaking project with a host of FinnCap clients who have managed to climb aboard the train just as it is leaving the station. No, not for them the miserable wait and unrelenting share price underperformance that the rest of us have had to endure these past 5 years. No, these guys are coming in at just the right moment, and i cannot criticise them for that, but the fact is that the share price was engineered downwards these past 6 months ( during which time most other pharma stocks were going bonkers ) thus providing an opportunity for these guys to buy in at an unrealistically low price. And that my friend is why the placing was over subscribed. I do not know if you are in contact with the company, but if you are then you should ask them why they did not insist on a higher price for the placing once it was obvious that it was going to be well over-subscribed. But then again our Directors do not actually have much skin in the game, so dilution is probably not going to keep them awake at night.
I have said it before and i will say it again, the prescence of FinnCap as a house broker is definitely a red flag.

[bumpa33] 07/2/2021 14:38

mm - you’re gonna have to learn to use that filter button soon fella.

This thread is going to get somewhat ‘busy’, imminently...

[moneymunch] 07/2/2021 12:04

ps great news from aTyr Pharma that further validates SFX-01's potential.....Exciting times!!! ;-)

[moneymunch] 07/2/2021 12:00

"Exciting developments in understanding inflammation and treating neutrophil dysfunction reviewed" ....the exciting developments made in Prof Chalmers lab could be highly significant for SFX-01 for Covid/ARDS and the reason why he has joined Evgen's Scientific Advisory Board at this pivotal stage as we await the assessment by the DSMB on the first 100 patients recruited. ....Gla Holders....Very exciting times for hose invested ;-)

ps the Smart Money is flooding in...;-)

...........................

29/1/21

James D Chalmers
@ProfJDChalmers
·
51m
New in @ERSpublications


Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism

Exciting developments in understanding inflammation and treating neutrophil dysfunction reviewed by the brilliant @GiamAshley

@Shoemelia
@dundeeuni
@UoDMedicine

...............


SFX-01 Phase 2b / phase 3 Covid/ARDS patient Trial.


Exploratory objectives

Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells

Neutrophil functional studies in isolated cells

Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood

[moneymunch] 07/2/2021 11:56

More on those neutrophils , that were highlighted by Prof Chalmers on Friday. Gla :-)

.......

November 2020

An opportunity has arisen for a Research Technician to support our internationally leading lung Infection laboratory at the University of Dundee. The group studies a range of lung infections including COVID-19.

You will be expected to provide high quality technical assistance to Professor Chalmers and the other members of the research team. Core tasks will include processing biological samples, isolating inflammatory cells such as neutrophils and measuring response to treatments using techniques such as ELISA and flow cytometry.

You will support the principal investigator, post-docs and PhD students as part of a multidisciplinary team, performing laboratory research to a high standard, organising study data and supervising undergraduates.

You will work collaboratively with team members to support multiple ongoing research studies including two national COVID-19 studies STOP-COVID ( and STAR-COVID





.....


Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Download PDF Copy

Dr. Liji Thomas, MDBy Dr. Liji Thomas, MDNov 15 2020

Coronavirus disease 2019 (COVID-19) cases continue to rise across the globe. Over 54.3 million people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of COVID-19 – and 1.31 million have lost their lives.

Scientists in Taiwan recently published a report on their use of anti-neutrophil strategies to treat acute respiratory distress syndrome (ARDS) – a life-threatening condition that can arise in critical COVID-19 cases – in the journal Frontiers in Pediatrics.

[moneymunch] 07/2/2021 11:52

Giam Ashley

29/1/21

James D Chalmers
@ProfJDChalmers
·
51m
New in @ERSpublications


Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism

Exciting developments in understanding inflammation and treating neutrophil dysfunction reviewed by the brilliant @GiamAshley

@Shoemelia
@dundeeuni
@UoDMedicine

...............


SFX-01 Phase 2b / phase 3 Covid/ARDS patient Trial.


Exploratory objectives

Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells

Neutrophil functional studies in isolated cells

Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood





.........................

Press Release
Covid-19 brings research switch for Ashley

Published on 25 June 2020

When Ashley Giam left Singapore for the UK, she could not have imagined that the move would lead to her working on potential treatments for the deadliest pandemic the world has seen for a century.

The projects Ashley has worked on include STOP-COVID19, the clinical trial of brensocatib, an anti-inflammatory drug that is hoped may help to prevent the worst ravages of the novel coronavirus. Ashley is also now playing a leading role in the study of another new anti-inflammatory drug called SFX-01. This medication reduces lung damage through the pathway that Ashley has been studying during her PhD. She is now working in the laboratory to understand whether this medicine could reduce the number of coronavirus patients requiring mechanical ventilation and, ultimately, cutting death rates from the disease.

[pugugly] 07/2/2021 11:42

Free FT Read - The horrors of ICU and coming out alive - A report from a survivor - The reason why every new successful treatment is needed

[nobbygnome] 07/2/2021 11:28

And just another thought as the rapid vaccine rollout occurs here in the U.K. the number of patients is going to drop off quick quickly in the next couple of months. Therefore, it would be wise not only to rely on U.K. hospitals to recruit patients. I wonder if they have any plans to open some sites in other countries such as Brazil or the US.

[nobbygnome] 07/2/2021 11:20

>> Mr greedy

Even if the 100th patient has been recruited the treatment and follow up period is 28 days. So no analysis will be done until the 100th patient has completed, which will be in March.

As I keep on saying, the false expectations created by some on this thread is one of the major problems here!

[moneymunch] 06/2/2021 18:56

Yep, extremely encouraging that Prof Chalmers has joined Evgen's Scientific Advisory Board, and very interesting at this stage of proceedings that the following research by Prof Dinkova-Kostova, who also is a Scientic advisor to Evgen and one of the lead investigators on SFX-01's Covid/ARDS trial and has a lifes work focused on NRF2 and all things Sulforaphane, was also included in the newly released Evgen Investor Presentation...all bodes well imho. Gla :')



.....

Can Activation of NRF2 Be a Strategy against COVID-19?

AntonioCuadrado

Albena T.Dinkova-Kostova

Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19.

[bocker01] 06/2/2021 17:20

One would imagine that the Prof thought it thru carefully..... and he’s a sharp cookie....

[mr greedy1] 06/2/2021 16:30

I guess if Prof Chambers has come on board it means the 100 reached and the results positive. Next week could be interesting!

[peanut100] 06/2/2021 16:17

Nothing will go out until after the record date as they know what shareholders are on the register at that date. Like an XD date

[peanut100] 06/2/2021 16:14

Sorry your post looks like you can buy 11 shares for everyone one held but it's 1 for 11.